Norges Bank’s LB Pharmaceuticals LBRX Stock Holding History

Norges Bank’s Portfolio LBRX Stock Details LBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-20,000	Closed	-$445K	–	1552
2025 Q4	$445K	Buy	+20,000	New	+$349K	﹤0.01%	1554

Other funds holding LBRX

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

SSC

Spruce Street Capital New York $416M AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

TECP

Trails Edge Capital Partners Atlanta, Georgia $437M AUM

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Norges Bank's LBRX Position: Q1 2026 in Review

Norges Bank sold out of LB Pharmaceuticals (LBRX) in Q1 2026, closing a stake of 20,000 shares — an estimated $445K sold.

Norges Bank first reported a position in LBRX in Q4 2025 and held it in 1 quarter. The position peaked at $445K in Q4 2025. 77 funds tracked by Wall St. Rank hold LBRX as of Q1 2026.

Norges Bank reported no remaining LB Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Norges Bank sold 20,000 LB Pharmaceuticals shares in Q1 2026, an estimated $445K.
Norges Bank first reported a position in LB Pharmaceuticals in Q4 2025 and held it in 1 quarter.
Norges Bank's LB Pharmaceuticals position peaked at $445K in Q4 2025.
77 funds tracked by Wall St. Rank held LB Pharmaceuticals as of Q1 2026.

Based on Norges Bank's 13F filing for Q1 2026.